Evidence map›Paper›PMID 39995854›Full record

ArticleiScience2025

The bacterial microbiome modulates the initiation of brain metastasis by impacting the gut-to-brain axis.

Matteo Massara, Michelle Ballabio, Bastien Dolfi, Golnaz Morad, Vladimir Wischnewski, Eleni Lamprou, Joao Lourenco, Stéphanie Claudinot, Hector Gallart-Ayala, Rui Santalla Méndez and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Metabolic adaptations of brain metastasis.Nature reviews. Cancer · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Matteo MassaraDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Michelle BallabioDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Bastien DolfiDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Golnaz MoradDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Vladimir WischnewskiDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Eleni LamprouDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Joao LourencoAgora Cancer Research Centre Lausanne, 1011 Lausanne, Switzerland.
Stéphanie ClaudinotGerm-free facility, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1066 Epalinges, Switzerland.
Hector Gallart-AyalaMetabolomics Unit, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Rui Santalla MéndezDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Annamaria KauzlaricAgora Cancer Research Centre Lausanne, 1011 Lausanne, Switzerland.
Nadine FournierAgora Cancer Research Centre Lausanne, 1011 Lausanne, Switzerland.
Ashish V DamaniaPlatform for Innovative Microbiome & Translational Research (PRIME-TR), Moon Shots™, Houston, TX 77054, USA.
Matthew C WongPlatform for Innovative Microbiome & Translational Research (PRIME-TR), Moon Shots™, Houston, TX 77054, USA.
Julijana IvanisevicMetabolomics Unit, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Nadim J AjamiPlatform for Innovative Microbiome & Translational Research (PRIME-TR), Moon Shots™, Houston, TX 77054, USA.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Johanna A JoyceDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.

Funding

(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiomeR01CA219896 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2018 to 2022
$2.2M
Elucidating the role of gut, blood, and tumor microbiota in brain metastasisF32CA260769 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORAD, GOLNAZ · 2021 to 2023
$205k
NCI NIH HHS F32 CA260769NCI NIH HHS R01 CA219896
6 · The paper itself

Abstract

Brain metastases (BrMs) are the most common brain tumors in patients and are associated with poor prognosis. Investigating the systemic and environmental factors regulating BrM biology represents an important strategy to develop effective treatments. Toward this goal, we explored the contribution of the gut microbiome to BrM development by using

Indexed as

CancerMicrobiomeMicroenvironment

Identifiers

PMID39995854
PMCPMC11848439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.